Быстрый заказ

4-1BB/TNFRSF9/CD137  Белок

All CD137  Reagents

Хозяин экспрессии: Human Cells  
10041-H08H-50
10041-H08H-100
50 µg 
100 µg 
Add to Cart
  • Slide 1
Описание продукта: Active  
Хозяин экспрессии: Human Cells  
10041-H03H-200
10041-H03H-100
200 µg 
100 µg 
Add to Cart
  • Slide 1
Хозяин экспрессии: Human Cells  
50811-M02H-50
50811-M02H-100
50 µg 
100 µg 
Add to Cart
  • Slide 1
Хозяин экспрессии: Human Cells  
70095-D08H-200
70095-D08H-100
200 µg 
100 µg 
Add to Cart
  • Slide 1
Хозяин экспрессии: Human Cells  
70095-D02H-200
70095-D02H-100
200 µg 
100 µg 
Add to Cart
  • Slide 1
Хозяин экспрессии: Human Cells  
90847-K08H-20
90847-K08H-100
20 µg 
100 µg 
Add to Cart
  • Slide 1
Хозяин экспрессии: Human Cells  
90847-K02H-20
90847-K02H-100
20 µg 
100 µg 
Add to Cart
  • Slide 1

Browse 4-1BB/TNFRSF9/CD137 Products by

4-1BB/TNFRSF9/CD137 Related Area

4-1BB/TNFRSF9/CD137 Связанные пути

4-1BB/TNFRSF9/CD137 Связанные продукты

4-1BB/TNFRSF9/CD137 Краткая информация и сведения о белках

4-1BB/TNFRSF9/CD137 Фон

Краткая информация о гене: The protein encoded by TNFRSF9 gene is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. The expression of this receptor is induced by lymphocyte activation. TRAF adaptor proteins have been shown to bind to this receptor and transduce the signals leading to activation of NF-kappaB. [provided by RefSeq, Jul 2008]
General information above from NCBI
Структура подгруппы: Interacts with TRAF1, TRAF2 and TRAF3. Interacts with LRR-repeat protein 1/LRR-1. {ECO:0000269|PubMed:11804328, ECO:0000269|PubMed:9418902, ECO:0000269|PubMed:9607925}.
Субклеточное местоположение: Membrane; Single-pass type I membrane protein.
Специфика ткани: Expressed on the surface of activated T-cells.
Сходство последовательностей: Contains 4 TNFR-Cys repeats. {ECO:0000255|PROSITE-ProRule:PRU00206}.
General information above from UniProt

CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.

Immune Checkpoint
Immune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies
Immune Checkpoint Proteins
Immune Checkpoint Targets   Co-stimulatory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy

4-1BB/TNFRSF9/CD137 Альтернативное название

4-1BB/TNFRSF9/CD137 Связанные исследования

  • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
  • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
  • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
  • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
  • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
  • Внимание: все продукты «ПРЕДНАЗНАЧЕНЫ ИСКЛЮЧИТЕЛЬНО ДЛЯ ИССЛЕДОВАНИЙ И НЕ ПРЕДНАЗНАЧЕНЫ ДЛЯ ДИАГНОСТИКИ ИЛИ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ».